Weinert, Tomas
Bernardoni, Fabio
King, Joseph
Steding, Julius
Boehm, Ilka
Mannigel, Merle
Ritschel, Franziska
Zepf, Florian
Roessner, Veit
Ehrlich, Stefan http://orcid.org/0000-0003-2132-4445
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (EH 367/5-1, SFB 940/2)
Technische Universität Dresden
Article History
Received: 21 January 2022
Accepted: 11 April 2022
First Online: 5 May 2022
Declarations
:
: V. Roessner has received payment for consulting and writing activities from Lilly, Novartis, and Shire Pharmaceuticals; lecture honoraria from Lilly, Novartis, Shire Pharmaceuticals, and Medice Pharma; and support for research from Shire and Novartis. He has carried out (and is currently carrying out) clinical trials in cooperation with Novartis, Shire, and Otsuka. The other authors declare that there is no conflict of interest.